Skip to main content
. 2002 Mar 5;99(5):3188–3193. doi: 10.1073/pnas.052712699

Table 1.

Regulation of DARPP-32 phosphorylation in vitro by 5-HT receptor agonists and antagonists

Thr34 Thr75 Ser137
Control 100 (17.0) 100 (5.0) 100 (3.9)
Serotonin 342 (26.7)** 76 (7.5)** 141 (6.0)**
5-HT receptor agonists
 PPB (5HT4 agonist) 218 (36.1)* 79 (8.8)* 107 (2.0)
 EMDT (5HT6 agonist) 301 (39.5)** 76 (7.6)** 103 (5.5)
 PPB + EMDT 397 (41.0)** 70 (3.8)** 105 (7.9)
 DOI (5HT2 agonist) 144 (10.7) 105 (4.5) 158 (8.3)**
 Anpirtoline (5HT1B agonist) 86 (3.7)* 102 (22.2) 93 (10.0)
 SR 57227 (5HT3 agonist) 78 (3.5)* 88 (6.8) 105 (9.6)
5-HT receptor antagonists
 SDZ 205,557 (5HT4 antagonist) 94 (16.7) 103 (17.5) 102 (8.8)
 SDZ + serotonin 257 (34.4)** 95 (11.5) 129 (5.0)*
 Ro 04-6790 (5HT6 antagonist) 90 (8.7) 101 (12.5) 105 (7.3)
 Ro + serotonin 225 (28.5)* 96 (8.4) 131 (7.2)*
 Ro + SDZ 84 (6.5) 110 (11.5) 107 (6.2)
 SDZ + Ro + serotonin 198 (44.5)* 98 (6.1) 134 (18.1)*
 Ketanserin (5HT2 antagonist) 94 (2.9) 105 (8.9) 97 (4.8)
 Ketanserin + serotonin 322 (28.4)** 78 (12.1)* 101 (9.1)
 Clozapine (5HT2/6 antagonist) 124 (19.8) 101 (13.4) 105 (5.5)
 Clozapine + serotonin 156 (15.4)* 98 (5.2) 110 (4.9)

Effects of serotonin (100 μM), PPB (100 μM), a 5-HT4 receptor agonist, EMDT (100 μM), a 5-HT6 receptor agonist, DOI (100 μM), a 5-HT2 receptor agonist, anpirtoline, (100 μM), a 5-HT1B receptor agonist, and SR 57227 (100 μM), a 5-HT3 receptor agonist, on Thr34, Thr75, and Ser137. In antagonist experiments, ketanserin (10 μM), a 5-HT2 receptor antagonist, SDZ 205,557 (10 μM), a 5-HT4 receptor antagonist, Ro 04-6790 (10 μM), a 5-HT6 receptor antagonist, or clozapine (10 μM), a multireceptor antagonist with high affinity for 5-HT2 and 5-HT6 receptors, was applied to striatal slices 10 min before serotonin (100 μM). Data represent means (± SEM) (n = 12–30). 

*

, P < 0.05; 

**

, P < 0.01; 

**

, P < 0.001 compared with control;  

, P < 0.05;  

, P < 0.01 compared with serotonin alone; one-way ANOVA followed by Dunnett's test.